Inserm — Sponsor Intelligence | 7 EU Trials

Filter these 7 trials by condition, phase, country and more.

Open in Search →

7 Registered trials

5 Recruiting

2 Completed trials

3 Countries active

12 Unique IMPs

100% Results reported

Phase III

Phase II

Phase III/IV

Phase I

Phase I (FiH)

Phase III: 2 Phase II: 2 Phase III/IV: 1 Phase I: 1 Phase I (FiH): 1

Oversight events:

3 temporary halts across 2 trials

View oversight register →

100%

2 of 2 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

COVID-19 2 HIV infection 1

Top IMPs

DOLUTEGRAVIR SODIUM 2 EMTRICITABINE, TENOFOVIR DISOPROXIL 2 BRETOVAMERAN 1 CABOTEGRAVIR 1 CABOTEGRAVIR SODIUM 1 DARUNAVIR 1 LAMIVUDINE 1 LAMIVUDINE, DORAVIRINE, TENOFOVIR DISOPROXIL 1 LVT-001 1 NIRMATRELVIR 1 REMDESIVIR 1 RITONAVIR 1

All trials

7 total

Interventional, multicenter, open-label, randomized, non-comparative trial evaluating the safety, in terms of HBV virological control, of 2 … Recruiting

2023-508634-34-00 Phase II 1 country DARUNAVIR; DOLUTEGRAVIR SODIUM; LAMIVUDINE; RITONAVIR
Randomized, controlled, multicenter Phase I/II study comparing the safety and immunogenicity of a booster dose of an intranasal COVID-19 vac… Recruiting

2024-510589-17-00 Phase I (FiH) 1 country BRETOVAMERAN; LVT-001
ANRS0392s ELDORADO : Phase III, open-label, randomized, multicenter trial EvaLuating the non-inferiority of DORAvirine versus DOlutegravir b… Recruiting

2023-508626-10-00 Phase III 1 country DOLUTEGRAVIR SODIUM; EMTRICITABINE, TENOFOVIR DISOPROXIL; LAMIVUDINE, DORAVIRINE…
A randomized controlled trial to evaluate the efficacy, acceptability and safety of event-driven pre-exposure prophylaxis for HIV using TAF/… Recruiting

2022-502931-20-00 Phase III 1 country
OPtimisation of antiviral Therapy in Immunocompromised COVID-19 patients: a randomized factorial controlled strategy trial: the OPTICOV Stud… Recruiting

2022-501408-81-01 Phase II 3 countries NIRMATRELVIR; REMDESIVIR
Impact of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis persistence and coverage in men who have sex with men in Fran… Ended

2024-510678-25-00 Phase III/IV 1 country CABOTEGRAVIR; CABOTEGRAVIR SODIUM; EMTRICITABINE, TENOFOVIR DISOPROXIL
ANRS0407s -LKV.Cov40. A phase 1/2 multicenter, randomized study of the safety and immunogenicity of a sub-unit protein CD40.RBDv bivalent CO… Ended

2023-504594-20-00 Phase I 1 country

Showing 1–7 of 7 trials

← All sponsors A–Z